This clinical trial is exploring whether PARP inhibitors will improve outcomes for patients with early-stage pancreas cancer that has BRCA or PALB2 mutations
A welcome to the new National Cancer Institute director, an update on the federal budget and its implications, and a look ahead to next week's Group Meeting
This phase 3 clinical trial is testing a new treatment approach for patients with treatment-refractory locally-advanced or metastatic urothelial cancer